 Truist has lowered the price target on IGM Biosciences Inc NASDAQ: IGMS to 74 from 80. The analyst Asthika Goonewardene says that the lower price target reflects the Companys Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA. 